Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;23(3):e3318.
doi: 10.1002/jgm.3318. Epub 2021 Feb 11.

Long non-coding RNAs: Promising new targets in pulmonary fibrosis

Affiliations
Review

Long non-coding RNAs: Promising new targets in pulmonary fibrosis

Songzi Zhang et al. J Gene Med. 2021 Mar.

Abstract

Pulmonary fibrosis is characterized by progressive and irreversible scarring in the lungs with poor prognosis and treatment. It is caused by various factors, including environmental and occupational exposures, and some rheumatic immune diseases. Even the rapid global spread of the COVID-19 pandemic can also cause pulmonary fibrosis with a high probability. Functions attributed to long non-coding RNAs (lncRNAs) make them highly attractive diagnostic and therapeutic targets in fibroproliferative diseases. Therefore, an understanding of the specific mechanisms by which lncRNAs regulate pulmonary fibrotic pathogenesis is urgently needed to identify new possibilities for therapy. In this review, we focus on the molecular mechanisms and implications of lncRNAs targeted protein-coding and non-coding genes during pulmonary fibrogenesis, and systematically analyze the communication of lncRNAs with various types of RNAs, including microRNA, circular RNA and mRNA. Finally, we propose the potential approach of lncRNA-based diagnosis and therapy for pulmonary fibrosis. We hope that understanding these interactions between protein-coding and non-coding genes will contribute to the development of lncRNA-based clinical applications for pulmonary fibrosis.

Keywords: COVID-19; circular RNA; lncRNA; microRNA; pulmonary fibrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Molecular mechanisms of lncRNAs and lncRNA‐based clinical applications in pulmonary fibrosis. Aging, environmental exposure or genetic predisposition to alveolar epithelial cell results in the release of pro‐fibrotic factors, such as growth factors, cytokines, chemokines and matrix metalloproteinases, which promote abnormal and persistent fibroblast activation and remodeling, macrophage M1/M2 polarization classification, and endothelial‐mesenchymal transition. Meanwhile, many abnormal organelles, including telomere attrition, endoplasmic reticulum stress and mitochondrial dysfunction, are also involved in fibrogenesis. lncRNAs participate in these abnormal biological processes in the nucleus or cytoplasm via diverse mechanisms and thus regulate numerous signaling pathways in different cell types to control pulmonary fibrogenesis. (1) The images present the various methodologies for lncRNA as the diagnostic marker. (2) lncRNA‐based therapeutic strategies are proposed depending on their different regulatory patterns
FIGURE 2
FIGURE 2
Regulatory paradigms of lncRNAs in pulmonary fibrosis. (A) lncRNA transcribed from the host gene, which affects the nearby/host genes. (B) lncRNA forms a RNA–protein complex by binding to specific protein to modulate the target gene activity. (C) lncRNA can be processed to yield miRNA or (D) function as a competing miRNA binding. (E) lncRNA cross‐talks with miRNA, circRNA and mRNA

Similar articles

Cited by

References

    1. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028‐1040. - PMC - PubMed
    1. Lampi MC, Reinhart‐King CA. Targeting extracellular matrix stiffness to attenuate disease: from molecular mechanisms to clinical trials. Sci Transl Med. 2018;10:422–435. - PubMed
    1. Mora AL, Rojas M, Pardo A, Selman M. Emerging therapies for idiopathic pulmonary fibrosis, a progressive age‐related disease. Nat Rev Drug Discov. 2017;16:755‐772. - PubMed
    1. Ooi GC, Khong PL, Müller NL, et al. Severe acute respiratory syndrome: temporal lung changes at thin‐section CT in 30 patients. Radiology. 2004;230:836‐844. - PubMed
    1. Chan KS, Zheng JP, Mok YW, et al. SARS: prognosis, outcome and sequelae. Respirology. 2003;8:S36‐S40. - PMC - PubMed

Publication types